Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

At first, the monovalent influenza A (H5N8) vaccine will be tested in two doses, 21 days apart, in adults aged 18–59.

The votes on vaccine recommendations are the first move by the panel after Health and Human Services Secretary Robert F.

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

A new slate of vaccine advisers to the US Centers for Disease Control and Prevention voted Thursday to recommend that ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The Trump administration's vaccine advisers have brought up an old flu-shot debate: Whether it's time to wipe out the last ...

U.S. Health Secretary Robert F. Kennedy Jr’s newly appointed Advisory Committee on Immunization Practices (ACIP) upheld ...

The preservative thimerosal started Robert F. Kennedy Jr. down the path of questioning vaccine safety. A panel of experts he ...